CD154 gene therapy - Tragen

Drug Profile

CD154 gene therapy - Tragen

Alternative Names: Ad-ISF154; ISF-154

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator University of California, San Diego
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action CD40 ligand stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV-infusion)
  • 17 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Cancer therapeutic trials section
  • 12 Sep 2003 A clinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top